nodes	percent_of_prediction	percent_of_DWPC	metapath
Paricalcitol—VDR—melanoma	0.662	1	CbGaD
Paricalcitol—CYP3A4—Temozolomide—melanoma	0.0428	0.576	CbGbCtD
Paricalcitol—CYP3A4—Vemurafenib—melanoma	0.0235	0.316	CbGbCtD
Paricalcitol—VDR—leg—melanoma	0.00841	0.205	CbGeAlD
Paricalcitol—CYP3A4—Docetaxel—melanoma	0.00805	0.108	CbGbCtD
Paricalcitol—VDR—hindlimb—melanoma	0.00751	0.183	CbGeAlD
Paricalcitol—VDR—appendage—melanoma	0.00644	0.157	CbGeAlD
Paricalcitol—VDR—skin epidermis—melanoma	0.00536	0.131	CbGeAlD
Paricalcitol—VDR—hair follicle—melanoma	0.00382	0.0932	CbGeAlD
Paricalcitol—VDR—neck—melanoma	0.00257	0.0625	CbGeAlD
Paricalcitol—VDR—eye—melanoma	0.00191	0.0465	CbGeAlD
Paricalcitol—Dihydrotachysterol—VDR—melanoma	0.00169	0.232	CrCbGaD
Paricalcitol—VDR—skin of body—melanoma	0.00166	0.0405	CbGeAlD
Paricalcitol—VDR—mammalian vulva—melanoma	0.00151	0.0369	CbGeAlD
Paricalcitol—Calcidiol—VDR—melanoma	0.00109	0.149	CrCbGaD
Paricalcitol—Calcipotriol—VDR—melanoma	0.00109	0.149	CrCbGaD
Paricalcitol—Alfacalcidol—VDR—melanoma	0.00109	0.149	CrCbGaD
Paricalcitol—VDR—head—melanoma	0.00108	0.0264	CbGeAlD
Paricalcitol—Calcitriol—VDR—melanoma	0.000971	0.133	CrCbGaD
Paricalcitol—Ergocalciferol—VDR—melanoma	0.000776	0.106	CrCbGaD
Paricalcitol—VDR—lymph node—melanoma	0.000759	0.0185	CbGeAlD
Paricalcitol—CYP24A1—Cytochrome P450 - arranged by substrate type—CYP1B1—melanoma	0.000663	0.00776	CbGpPWpGaD
Paricalcitol—UGT1A4—Aryl Hydrocarbon Receptor Pathway—CYP1B1—melanoma	0.000655	0.00767	CbGpPWpGaD
Paricalcitol—CYP24A1—Oxidation by Cytochrome P450—CYP1B1—melanoma	0.000654	0.00765	CbGpPWpGaD
Paricalcitol—UGT1A4—NRF2 pathway—EPHA2—melanoma	0.000653	0.00765	CbGpPWpGaD
Paricalcitol—VDR—Direct p53 effectors—GDF15—melanoma	0.000648	0.00758	CbGpPWpGaD
Paricalcitol—CYP24A1—Metapathway biotransformation—AKR1B10—melanoma	0.000647	0.00757	CbGpPWpGaD
Paricalcitol—CYP24A1—Phase 1 - Functionalization of compounds—CYP17A1—melanoma	0.000638	0.00747	CbGpPWpGaD
Paricalcitol—VDR—RXR and RAR heterodimerization with other nuclear receptor—PPARG—melanoma	0.000621	0.00727	CbGpPWpGaD
Paricalcitol—UGT1A4—NRF2 pathway—SLC6A11—melanoma	0.000614	0.00719	CbGpPWpGaD
Paricalcitol—CYP24A1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—melanoma	0.000598	0.007	CbGpPWpGaD
Paricalcitol—Cholecalciferol—VDR—melanoma	0.000588	0.0807	CrCbGaD
Paricalcitol—VDR—Ovarian Infertility Genes—ATM—melanoma	0.000582	0.00681	CbGpPWpGaD
Paricalcitol—VDR—Ovarian Infertility Genes—CDK4—melanoma	0.000579	0.00678	CbGpPWpGaD
Paricalcitol—CYP24A1—Phase 1 - Functionalization of compounds—CYP1B1—melanoma	0.000537	0.00629	CbGpPWpGaD
Paricalcitol—VDR—Direct p53 effectors—MCL1—melanoma	0.000537	0.00628	CbGpPWpGaD
Paricalcitol—VDR—Direct p53 effectors—TP73—melanoma	0.000537	0.00628	CbGpPWpGaD
Paricalcitol—VDR—Direct p53 effectors—NDRG1—melanoma	0.000537	0.00628	CbGpPWpGaD
Paricalcitol—UGT1A4—Metapathway biotransformation—AKR1B10—melanoma	0.000517	0.00605	CbGpPWpGaD
Paricalcitol—VDR—RXR and RAR heterodimerization with other nuclear receptor—BCL2—melanoma	0.000514	0.00602	CbGpPWpGaD
Paricalcitol—VDR—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—melanoma	0.000501	0.00587	CbGpPWpGaD
Paricalcitol—VDR—Direct p53 effectors—CASP10—melanoma	0.000478	0.0056	CbGpPWpGaD
Paricalcitol—VDR—Regulation of nuclear SMAD2/3 signaling—HDAC2—melanoma	0.000461	0.00539	CbGpPWpGaD
Paricalcitol—VDR—Regulation of nuclear SMAD2/3 signaling—FOXO4—melanoma	0.000461	0.00539	CbGpPWpGaD
Paricalcitol—VDR—Nuclear Receptors—PPARG—melanoma	0.000459	0.00537	CbGpPWpGaD
Paricalcitol—VDR—Regulation of nuclear SMAD2/3 signaling—IFNB1—melanoma	0.000452	0.00529	CbGpPWpGaD
Paricalcitol—VDR—Validated transcriptional targets of TAp63 isoforms—FAS—melanoma	0.000433	0.00507	CbGpPWpGaD
Paricalcitol—VDR—Direct p53 effectors—APAF1—melanoma	0.000429	0.00502	CbGpPWpGaD
Paricalcitol—VDR—Validated transcriptional targets of deltaNp63 isoforms—ATM—melanoma	0.000428	0.005	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—ACER3—melanoma	0.000427	0.005	CbGpPWpGaD
Paricalcitol—VDR—Validated transcriptional targets of deltaNp63 isoforms—NOTCH1—melanoma	0.00041	0.0048	CbGpPWpGaD
Paricalcitol—VDR—Direct p53 effectors—VCAN—melanoma	0.000397	0.00465	CbGpPWpGaD
Paricalcitol—CYP3A4—Liver X Receptor Pathway—FASN—melanoma	0.000396	0.00463	CbGpPWpGaD
Paricalcitol—CYP3A4—Benzo(a)pyrene metabolism—CYP1B1—melanoma	0.000392	0.00459	CbGpPWpGaD
Paricalcitol—VDR—Ovarian Infertility Genes—CDKN1B—melanoma	0.000392	0.00459	CbGpPWpGaD
Paricalcitol—VDR—Direct p53 effectors—MSH2—melanoma	0.000388	0.00454	CbGpPWpGaD
Paricalcitol—VDR—Regulation of nuclear SMAD2/3 signaling—CDKN2B—melanoma	0.000368	0.00431	CbGpPWpGaD
Paricalcitol—VDR—Nuclear Receptor transcription pathway—PPARG—melanoma	0.000362	0.00424	CbGpPWpGaD
Paricalcitol—CYP3A4—Codeine and Morphine Metabolism—ABCB1—melanoma	0.000355	0.00415	CbGpPWpGaD
Paricalcitol—Sinusitis—Temozolomide—melanoma	0.000352	0.00272	CcSEcCtD
Paricalcitol—VDR—Direct p53 effectors—MLH1—melanoma	0.00035	0.00409	CbGpPWpGaD
Paricalcitol—VDR—Regulation of nuclear SMAD2/3 signaling—IL10—melanoma	0.000349	0.00409	CbGpPWpGaD
Paricalcitol—Hypoaesthesia—Carmustine—melanoma	0.000347	0.00268	CcSEcCtD
Paricalcitol—Hypersensitivity—Vemurafenib—melanoma	0.000345	0.00267	CcSEcCtD
Paricalcitol—Oedema peripheral—Carmustine—melanoma	0.000344	0.00266	CcSEcCtD
Paricalcitol—Connective tissue disorder—Carmustine—melanoma	0.000343	0.00265	CcSEcCtD
Paricalcitol—Dermatitis bullous—Docetaxel—melanoma	0.000339	0.00262	CcSEcCtD
Paricalcitol—CYP24A1—Biological oxidations—CYP17A1—melanoma	0.000339	0.00397	CbGpPWpGaD
Paricalcitol—Asthenia—Vemurafenib—melanoma	0.000336	0.0026	CcSEcCtD
Paricalcitol—Hypoaesthesia—Temozolomide—melanoma	0.000335	0.00259	CcSEcCtD
Paricalcitol—Pharyngitis—Temozolomide—melanoma	0.000335	0.00259	CcSEcCtD
Paricalcitol—Chills—Dactinomycin—melanoma	0.000334	0.00258	CcSEcCtD
Paricalcitol—CYP24A1—Metapathway biotransformation—CYP17A1—melanoma	0.000334	0.00391	CbGpPWpGaD
Paricalcitol—Urinary tract disorder—Temozolomide—melanoma	0.000333	0.00257	CcSEcCtD
Paricalcitol—Oedema peripheral—Temozolomide—melanoma	0.000332	0.00257	CcSEcCtD
Paricalcitol—Pruritus—Vemurafenib—melanoma	0.000332	0.00256	CcSEcCtD
Paricalcitol—Connective tissue disorder—Temozolomide—melanoma	0.000331	0.00256	CcSEcCtD
Paricalcitol—Urethral disorder—Temozolomide—melanoma	0.00033	0.00255	CcSEcCtD
Paricalcitol—VDR—RXR and RAR heterodimerization with other nuclear receptor—TNF—melanoma	0.00033	0.00386	CbGpPWpGaD
Paricalcitol—Alopecia—Dactinomycin—melanoma	0.000329	0.00255	CcSEcCtD
Paricalcitol—Eye disorder—Carmustine—melanoma	0.000326	0.00252	CcSEcCtD
Paricalcitol—VDR—Validated transcriptional targets of deltaNp63 isoforms—CDKN2A—melanoma	0.000325	0.00381	CbGpPWpGaD
Paricalcitol—VDR—Retinoic acid receptors-mediated signaling—MAPK3—melanoma	0.000325	0.0038	CbGpPWpGaD
Paricalcitol—Gastrointestinal haemorrhage—Docetaxel—melanoma	0.000324	0.0025	CcSEcCtD
Paricalcitol—Ill-defined disorder—Bleomycin—melanoma	0.000323	0.00249	CcSEcCtD
Paricalcitol—Anaemia—Bleomycin—melanoma	0.000322	0.00249	CcSEcCtD
Paricalcitol—Diarrhoea—Vemurafenib—melanoma	0.000321	0.00248	CcSEcCtD
Paricalcitol—VDR—Validated transcriptional targets of deltaNp63 isoforms—MDM2—melanoma	0.000316	0.00369	CbGpPWpGaD
Paricalcitol—Eye disorder—Temozolomide—melanoma	0.000315	0.00243	CcSEcCtD
Paricalcitol—Malaise—Bleomycin—melanoma	0.000314	0.00242	CcSEcCtD
Paricalcitol—Cardiac disorder—Temozolomide—melanoma	0.000313	0.00242	CcSEcCtD
Paricalcitol—Arrhythmia—Carmustine—melanoma	0.000312	0.00241	CcSEcCtD
Paricalcitol—Leukopenia—Bleomycin—melanoma	0.000311	0.00241	CcSEcCtD
Paricalcitol—Dizziness—Vemurafenib—melanoma	0.00031	0.0024	CcSEcCtD
Paricalcitol—VDR—Retinoic acid receptors-mediated signaling—MAPK1—melanoma	0.000309	0.00362	CbGpPWpGaD
Paricalcitol—Alopecia—Carmustine—melanoma	0.000308	0.00238	CcSEcCtD
Paricalcitol—UGT1A4—Aryl Hydrocarbon Receptor Pathway—IFNG—melanoma	0.000308	0.0036	CbGpPWpGaD
Paricalcitol—Angiopathy—Temozolomide—melanoma	0.000306	0.00236	CcSEcCtD
Paricalcitol—Mental disorder—Carmustine—melanoma	0.000306	0.00236	CcSEcCtD
Paricalcitol—Immune system disorder—Temozolomide—melanoma	0.000305	0.00235	CcSEcCtD
Paricalcitol—Mediastinal disorder—Temozolomide—melanoma	0.000304	0.00235	CcSEcCtD
Paricalcitol—Malnutrition—Carmustine—melanoma	0.000304	0.00235	CcSEcCtD
Paricalcitol—Cough—Bleomycin—melanoma	0.000304	0.00235	CcSEcCtD
Paricalcitol—Chills—Temozolomide—melanoma	0.000303	0.00234	CcSEcCtD
Paricalcitol—Dehydration—Docetaxel—melanoma	0.000301	0.00233	CcSEcCtD
Paricalcitol—Ill-defined disorder—Dactinomycin—melanoma	0.000301	0.00233	CcSEcCtD
Paricalcitol—Anaemia—Dactinomycin—melanoma	0.0003	0.00232	CcSEcCtD
Paricalcitol—Vomiting—Vemurafenib—melanoma	0.000298	0.0023	CcSEcCtD
Paricalcitol—Alopecia—Temozolomide—melanoma	0.000298	0.0023	CcSEcCtD
Paricalcitol—VDR—Direct p53 effectors—HDAC2—melanoma	0.000297	0.00348	CbGpPWpGaD
Paricalcitol—Myalgia—Bleomycin—melanoma	0.000296	0.00229	CcSEcCtD
Paricalcitol—Chest pain—Bleomycin—melanoma	0.000296	0.00229	CcSEcCtD
Paricalcitol—Rash—Vemurafenib—melanoma	0.000296	0.00228	CcSEcCtD
Paricalcitol—Mental disorder—Temozolomide—melanoma	0.000295	0.00228	CcSEcCtD
Paricalcitol—Dermatitis—Vemurafenib—melanoma	0.000295	0.00228	CcSEcCtD
Paricalcitol—Back pain—Carmustine—melanoma	0.000294	0.00227	CcSEcCtD
Paricalcitol—Headache—Vemurafenib—melanoma	0.000294	0.00227	CcSEcCtD
Paricalcitol—Malnutrition—Temozolomide—melanoma	0.000293	0.00227	CcSEcCtD
Paricalcitol—Breast disorder—Docetaxel—melanoma	0.000293	0.00226	CcSEcCtD
Paricalcitol—Discomfort—Bleomycin—melanoma	0.000293	0.00226	CcSEcCtD
Paricalcitol—Malaise—Dactinomycin—melanoma	0.000293	0.00226	CcSEcCtD
Paricalcitol—Aspartate aminotransferase increased—Docetaxel—melanoma	0.000292	0.00226	CcSEcCtD
Paricalcitol—VDR—Regulation of nuclear SMAD2/3 signaling—CDK2—melanoma	0.000292	0.00341	CbGpPWpGaD
Paricalcitol—VDR—Validated transcriptional targets of TAp63 isoforms—CDKN2A—melanoma	0.000291	0.00341	CbGpPWpGaD
Paricalcitol—Leukopenia—Dactinomycin—melanoma	0.00029	0.00224	CcSEcCtD
Paricalcitol—Nasopharyngitis—Docetaxel—melanoma	0.00029	0.00224	CcSEcCtD
Paricalcitol—Dysgeusia—Temozolomide—melanoma	0.000287	0.00222	CcSEcCtD
Paricalcitol—Confusional state—Bleomycin—melanoma	0.000286	0.00221	CcSEcCtD
Paricalcitol—CYP24A1—Biological oxidations—CYP1B1—melanoma	0.000285	0.00334	CbGpPWpGaD
Paricalcitol—Oedema—Bleomycin—melanoma	0.000284	0.00219	CcSEcCtD
Paricalcitol—Back pain—Temozolomide—melanoma	0.000284	0.00219	CcSEcCtD
Paricalcitol—VDR—Validated transcriptional targets of TAp63 isoforms—MDM2—melanoma	0.000283	0.00331	CbGpPWpGaD
Paricalcitol—Infection—Bleomycin—melanoma	0.000282	0.00218	CcSEcCtD
Paricalcitol—CYP24A1—Metapathway biotransformation—CYP1B1—melanoma	0.000282	0.00329	CbGpPWpGaD
Paricalcitol—UGT1A4—NRF2 pathway—SLC5A5—melanoma	0.000281	0.00329	CbGpPWpGaD
Paricalcitol—Anaemia—Carmustine—melanoma	0.000281	0.00217	CcSEcCtD
Paricalcitol—Dysphagia—Docetaxel—melanoma	0.00028	0.00216	CcSEcCtD
Paricalcitol—UGT1A4—Aryl Hydrocarbon Receptor Pathway—CDKN1B—melanoma	0.00028	0.00327	CbGpPWpGaD
Paricalcitol—Agitation—Carmustine—melanoma	0.000279	0.00216	CcSEcCtD
Paricalcitol—Nausea—Vemurafenib—melanoma	0.000278	0.00215	CcSEcCtD
Paricalcitol—Myalgia—Dactinomycin—melanoma	0.000276	0.00214	CcSEcCtD
Paricalcitol—VDR—Regulation of nuclear SMAD2/3 signaling—CDK4—melanoma	0.000276	0.00322	CbGpPWpGaD
Paricalcitol—UGT1A4—Aryl Hydrocarbon Receptor Pathway—IL2—melanoma	0.000274	0.0032	CbGpPWpGaD
Paricalcitol—Discomfort—Dactinomycin—melanoma	0.000273	0.00211	CcSEcCtD
Paricalcitol—Ill-defined disorder—Temozolomide—melanoma	0.000272	0.0021	CcSEcCtD
Paricalcitol—Leukopenia—Carmustine—melanoma	0.000272	0.0021	CcSEcCtD
Paricalcitol—Anaemia—Temozolomide—melanoma	0.000271	0.0021	CcSEcCtD
Paricalcitol—UGT1A4—Biological oxidations—CYP17A1—melanoma	0.000271	0.00317	CbGpPWpGaD
Paricalcitol—Anorexia—Bleomycin—melanoma	0.000271	0.00209	CcSEcCtD
Paricalcitol—Agitation—Temozolomide—melanoma	0.00027	0.00208	CcSEcCtD
Paricalcitol—Angioedema—Temozolomide—melanoma	0.000268	0.00207	CcSEcCtD
Paricalcitol—UGT1A4—Metapathway biotransformation—CYP17A1—melanoma	0.000267	0.00313	CbGpPWpGaD
Paricalcitol—Hypotension—Bleomycin—melanoma	0.000265	0.00205	CcSEcCtD
Paricalcitol—Oedema—Dactinomycin—melanoma	0.000265	0.00205	CcSEcCtD
Paricalcitol—Malaise—Temozolomide—melanoma	0.000265	0.00205	CcSEcCtD
Paricalcitol—Vertigo—Temozolomide—melanoma	0.000264	0.00204	CcSEcCtD
Paricalcitol—Infection—Dactinomycin—melanoma	0.000263	0.00203	CcSEcCtD
Paricalcitol—Leukopenia—Temozolomide—melanoma	0.000263	0.00203	CcSEcCtD
Paricalcitol—Hypertension—Carmustine—melanoma	0.000262	0.00203	CcSEcCtD
Paricalcitol—Palpitations—Temozolomide—melanoma	0.000259	0.002	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—PIP4K2A—melanoma	0.000259	0.00303	CbGpPWpGaD
Paricalcitol—Musculoskeletal discomfort—Bleomycin—melanoma	0.000259	0.002	CcSEcCtD
Paricalcitol—Myalgia—Carmustine—melanoma	0.000259	0.002	CcSEcCtD
Paricalcitol—Chest pain—Carmustine—melanoma	0.000259	0.002	CcSEcCtD
Paricalcitol—Anxiety—Carmustine—melanoma	0.000258	0.00199	CcSEcCtD
Paricalcitol—Cough—Temozolomide—melanoma	0.000256	0.00198	CcSEcCtD
Paricalcitol—Paraesthesia—Bleomycin—melanoma	0.000255	0.00197	CcSEcCtD
Paricalcitol—Weight decreased—Docetaxel—melanoma	0.000253	0.00196	CcSEcCtD
Paricalcitol—Hypertension—Temozolomide—melanoma	0.000253	0.00196	CcSEcCtD
Paricalcitol—Dyspnoea—Bleomycin—melanoma	0.000253	0.00196	CcSEcCtD
Paricalcitol—Anorexia—Dactinomycin—melanoma	0.000252	0.00195	CcSEcCtD
Paricalcitol—Pneumonia—Docetaxel—melanoma	0.000251	0.00194	CcSEcCtD
Paricalcitol—Confusional state—Carmustine—melanoma	0.00025	0.00193	CcSEcCtD
Paricalcitol—Arthralgia—Temozolomide—melanoma	0.00025	0.00193	CcSEcCtD
Paricalcitol—Myalgia—Temozolomide—melanoma	0.00025	0.00193	CcSEcCtD
Paricalcitol—Infestation NOS—Docetaxel—melanoma	0.00025	0.00193	CcSEcCtD
Paricalcitol—Infestation—Docetaxel—melanoma	0.00025	0.00193	CcSEcCtD
Paricalcitol—Anxiety—Temozolomide—melanoma	0.000249	0.00192	CcSEcCtD
Paricalcitol—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.000248	0.00192	CcSEcCtD
Paricalcitol—Oedema—Carmustine—melanoma	0.000248	0.00192	CcSEcCtD
Paricalcitol—Discomfort—Temozolomide—melanoma	0.000247	0.00191	CcSEcCtD
Paricalcitol—Decreased appetite—Bleomycin—melanoma	0.000247	0.00191	CcSEcCtD
Paricalcitol—Infection—Carmustine—melanoma	0.000246	0.0019	CcSEcCtD
Paricalcitol—Dry mouth—Temozolomide—melanoma	0.000244	0.00189	CcSEcCtD
Paricalcitol—Pain—Bleomycin—melanoma	0.000243	0.00188	CcSEcCtD
Paricalcitol—Conjunctivitis—Docetaxel—melanoma	0.000243	0.00188	CcSEcCtD
Paricalcitol—Confusional state—Temozolomide—melanoma	0.000242	0.00187	CcSEcCtD
Paricalcitol—Musculoskeletal discomfort—Dactinomycin—melanoma	0.000241	0.00186	CcSEcCtD
Paricalcitol—Oedema—Temozolomide—melanoma	0.00024	0.00185	CcSEcCtD
Paricalcitol—VDR—Validated transcriptional targets of TAp63 isoforms—CDKN1A—melanoma	0.000238	0.00279	CbGpPWpGaD
Paricalcitol—Infection—Temozolomide—melanoma	0.000238	0.00184	CcSEcCtD
Paricalcitol—Anorexia—Carmustine—melanoma	0.000236	0.00183	CcSEcCtD
Paricalcitol—Epistaxis—Docetaxel—melanoma	0.000236	0.00182	CcSEcCtD
Paricalcitol—Nervous system disorder—Temozolomide—melanoma	0.000235	0.00182	CcSEcCtD
Paricalcitol—Feeling abnormal—Bleomycin—melanoma	0.000234	0.00181	CcSEcCtD
Paricalcitol—Skin disorder—Temozolomide—melanoma	0.000233	0.0018	CcSEcCtD
Paricalcitol—Hypotension—Carmustine—melanoma	0.000232	0.00179	CcSEcCtD
Paricalcitol—Hyperhidrosis—Temozolomide—melanoma	0.000232	0.00179	CcSEcCtD
Paricalcitol—Decreased appetite—Dactinomycin—melanoma	0.00023	0.00178	CcSEcCtD
Paricalcitol—VDR—Gene Expression—CLNS1A—melanoma	0.00023	0.00269	CbGpPWpGaD
Paricalcitol—Fatigue—Dactinomycin—melanoma	0.000228	0.00176	CcSEcCtD
Paricalcitol—Anorexia—Temozolomide—melanoma	0.000228	0.00176	CcSEcCtD
Paricalcitol—UGT1A4—Biological oxidations—CYP1B1—melanoma	0.000228	0.00267	CbGpPWpGaD
Paricalcitol—Pain—Dactinomycin—melanoma	0.000226	0.00175	CcSEcCtD
Paricalcitol—Musculoskeletal discomfort—Carmustine—melanoma	0.000226	0.00175	CcSEcCtD
Paricalcitol—Urticaria—Bleomycin—melanoma	0.000226	0.00174	CcSEcCtD
Paricalcitol—VDR—Direct p53 effectors—HGF—melanoma	0.000225	0.00264	CbGpPWpGaD
Paricalcitol—CYP3A4—Estrogen metabolism—CYP1B1—melanoma	0.000225	0.00264	CbGpPWpGaD
Paricalcitol—UGT1A4—Metapathway biotransformation—CYP1B1—melanoma	0.000225	0.00263	CbGpPWpGaD
Paricalcitol—Body temperature increased—Bleomycin—melanoma	0.000224	0.00173	CcSEcCtD
Paricalcitol—Insomnia—Carmustine—melanoma	0.000224	0.00173	CcSEcCtD
Paricalcitol—Hypoaesthesia—Docetaxel—melanoma	0.000223	0.00172	CcSEcCtD
Paricalcitol—Paraesthesia—Carmustine—melanoma	0.000223	0.00172	CcSEcCtD
Paricalcitol—Pharyngitis—Docetaxel—melanoma	0.000223	0.00172	CcSEcCtD
Paricalcitol—Urinary tract disorder—Docetaxel—melanoma	0.000221	0.00171	CcSEcCtD
Paricalcitol—Dyspnoea—Carmustine—melanoma	0.000221	0.00171	CcSEcCtD
Paricalcitol—Oedema peripheral—Docetaxel—melanoma	0.000221	0.00171	CcSEcCtD
Paricalcitol—Somnolence—Carmustine—melanoma	0.00022	0.0017	CcSEcCtD
Paricalcitol—Connective tissue disorder—Docetaxel—melanoma	0.00022	0.0017	CcSEcCtD
Paricalcitol—Urethral disorder—Docetaxel—melanoma	0.00022	0.0017	CcSEcCtD
Paricalcitol—VDR—Retinoic acid receptors-mediated signaling—AKT1—melanoma	0.000219	0.00256	CbGpPWpGaD
Paricalcitol—Feeling abnormal—Dactinomycin—melanoma	0.000218	0.00169	CcSEcCtD
Paricalcitol—Musculoskeletal discomfort—Temozolomide—melanoma	0.000218	0.00169	CcSEcCtD
Paricalcitol—VDR—Direct p53 effectors—E2F1—melanoma	0.000218	0.00255	CbGpPWpGaD
Paricalcitol—Insomnia—Temozolomide—melanoma	0.000217	0.00167	CcSEcCtD
Paricalcitol—Gastrointestinal pain—Dactinomycin—melanoma	0.000217	0.00167	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—CUBN—melanoma	0.000216	0.00253	CbGpPWpGaD
Paricalcitol—Decreased appetite—Carmustine—melanoma	0.000215	0.00167	CcSEcCtD
Paricalcitol—Paraesthesia—Temozolomide—melanoma	0.000215	0.00166	CcSEcCtD
Paricalcitol—Gastrointestinal disorder—Carmustine—melanoma	0.000214	0.00165	CcSEcCtD
Paricalcitol—Dyspnoea—Temozolomide—melanoma	0.000214	0.00165	CcSEcCtD
Paricalcitol—Somnolence—Temozolomide—melanoma	0.000213	0.00165	CcSEcCtD
Paricalcitol—Constipation—Carmustine—melanoma	0.000212	0.00164	CcSEcCtD
Paricalcitol—Pain—Carmustine—melanoma	0.000212	0.00164	CcSEcCtD
Paricalcitol—Dyspepsia—Temozolomide—melanoma	0.000211	0.00163	CcSEcCtD
Paricalcitol—VDR—Direct p53 effectors—SPP1—melanoma	0.00021	0.00245	CbGpPWpGaD
Paricalcitol—Eye disorder—Docetaxel—melanoma	0.00021	0.00162	CcSEcCtD
Paricalcitol—UGT1A4—Aryl Hydrocarbon Receptor Pathway—EGFR—melanoma	0.000209	0.00245	CbGpPWpGaD
Paricalcitol—Body temperature increased—Dactinomycin—melanoma	0.000209	0.00162	CcSEcCtD
Paricalcitol—Abdominal pain—Dactinomycin—melanoma	0.000209	0.00162	CcSEcCtD
Paricalcitol—Hypersensitivity—Bleomycin—melanoma	0.000209	0.00162	CcSEcCtD
Paricalcitol—Decreased appetite—Temozolomide—melanoma	0.000208	0.00161	CcSEcCtD
Paricalcitol—Cardiac disorder—Docetaxel—melanoma	0.000208	0.00161	CcSEcCtD
Paricalcitol—UGT1A4—NRF2 pathway—HGF—melanoma	0.000208	0.00243	CbGpPWpGaD
Paricalcitol—Gastrointestinal disorder—Temozolomide—melanoma	0.000207	0.0016	CcSEcCtD
Paricalcitol—Fatigue—Temozolomide—melanoma	0.000207	0.0016	CcSEcCtD
Paricalcitol—VDR—Direct p53 effectors—PCNA—melanoma	0.000206	0.00241	CbGpPWpGaD
Paricalcitol—Pain—Temozolomide—melanoma	0.000205	0.00158	CcSEcCtD
Paricalcitol—Constipation—Temozolomide—melanoma	0.000205	0.00158	CcSEcCtD
Paricalcitol—Feeling abnormal—Carmustine—melanoma	0.000204	0.00158	CcSEcCtD
Paricalcitol—Asthenia—Bleomycin—melanoma	0.000204	0.00157	CcSEcCtD
Paricalcitol—Angiopathy—Docetaxel—melanoma	0.000203	0.00157	CcSEcCtD
Paricalcitol—Gastrointestinal pain—Carmustine—melanoma	0.000203	0.00157	CcSEcCtD
Paricalcitol—Immune system disorder—Docetaxel—melanoma	0.000203	0.00157	CcSEcCtD
Paricalcitol—VDR—Direct p53 effectors—FAS—melanoma	0.000202	0.00236	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—GPAM—melanoma	0.000202	0.00236	CbGpPWpGaD
Paricalcitol—Mediastinal disorder—Docetaxel—melanoma	0.000202	0.00156	CcSEcCtD
Paricalcitol—VDR—Generic Transcription Pathway—SKI—melanoma	0.000201	0.00236	CbGpPWpGaD
Paricalcitol—Chills—Docetaxel—melanoma	0.000201	0.00155	CcSEcCtD
Paricalcitol—Pruritus—Bleomycin—melanoma	0.000201	0.00155	CcSEcCtD
Paricalcitol—Arrhythmia—Docetaxel—melanoma	0.0002	0.00155	CcSEcCtD
Paricalcitol—UGT1A4—Aryl Hydrocarbon Receptor Pathway—TNF—melanoma	0.000199	0.00233	CbGpPWpGaD
Paricalcitol—CYP3A4—Tamoxifen metabolism—CYP1B1—melanoma	0.000199	0.00233	CbGpPWpGaD
Paricalcitol—Alopecia—Docetaxel—melanoma	0.000198	0.00153	CcSEcCtD
Paricalcitol—Feeling abnormal—Temozolomide—melanoma	0.000197	0.00153	CcSEcCtD
Paricalcitol—Mental disorder—Docetaxel—melanoma	0.000196	0.00152	CcSEcCtD
Paricalcitol—Abdominal pain—Carmustine—melanoma	0.000196	0.00151	CcSEcCtD
Paricalcitol—Body temperature increased—Carmustine—melanoma	0.000196	0.00151	CcSEcCtD
Paricalcitol—Gastrointestinal pain—Temozolomide—melanoma	0.000196	0.00151	CcSEcCtD
Paricalcitol—Malnutrition—Docetaxel—melanoma	0.000195	0.00151	CcSEcCtD
Paricalcitol—Hypersensitivity—Dactinomycin—melanoma	0.000195	0.00151	CcSEcCtD
Paricalcitol—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—melanoma	0.000194	0.00227	CbGpPWpGaD
Paricalcitol—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—melanoma	0.000194	0.00227	CbGpPWpGaD
Paricalcitol—Dysgeusia—Docetaxel—melanoma	0.000191	0.00148	CcSEcCtD
Paricalcitol—Urticaria—Temozolomide—melanoma	0.00019	0.00147	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism—ACER3—melanoma	0.00019	0.00223	CbGpPWpGaD
Paricalcitol—Asthenia—Dactinomycin—melanoma	0.00019	0.00147	CcSEcCtD
Paricalcitol—Abdominal pain—Temozolomide—melanoma	0.000189	0.00146	CcSEcCtD
Paricalcitol—Body temperature increased—Temozolomide—melanoma	0.000189	0.00146	CcSEcCtD
Paricalcitol—Back pain—Docetaxel—melanoma	0.000189	0.00146	CcSEcCtD
Paricalcitol—Muscle spasms—Docetaxel—melanoma	0.000188	0.00145	CcSEcCtD
Paricalcitol—Hypersensitivity—Carmustine—melanoma	0.000183	0.00141	CcSEcCtD
Paricalcitol—Diarrhoea—Dactinomycin—melanoma	0.000181	0.0014	CcSEcCtD
Paricalcitol—Vomiting—Bleomycin—melanoma	0.000181	0.0014	CcSEcCtD
Paricalcitol—Anaemia—Docetaxel—melanoma	0.00018	0.00139	CcSEcCtD
Paricalcitol—Rash—Bleomycin—melanoma	0.000179	0.00138	CcSEcCtD
Paricalcitol—Dermatitis—Bleomycin—melanoma	0.000179	0.00138	CcSEcCtD
Paricalcitol—VDR—Direct p53 effectors—MET—melanoma	0.000178	0.00208	CbGpPWpGaD
Paricalcitol—Asthenia—Carmustine—melanoma	0.000178	0.00137	CcSEcCtD
Paricalcitol—Hypersensitivity—Temozolomide—melanoma	0.000176	0.00136	CcSEcCtD
Paricalcitol—Syncope—Docetaxel—melanoma	0.000175	0.00135	CcSEcCtD
Paricalcitol—Leukopenia—Docetaxel—melanoma	0.000175	0.00135	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism—UGT2B10—melanoma	0.000174	0.00204	CbGpPWpGaD
Paricalcitol—Palpitations—Docetaxel—melanoma	0.000172	0.00133	CcSEcCtD
Paricalcitol—VDR—Regulation of nuclear SMAD2/3 signaling—CDKN1A—melanoma	0.000172	0.00201	CbGpPWpGaD
Paricalcitol—Asthenia—Temozolomide—melanoma	0.000172	0.00133	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—PLA2G6—melanoma	0.000172	0.00201	CbGpPWpGaD
Paricalcitol—Loss of consciousness—Docetaxel—melanoma	0.000172	0.00133	CcSEcCtD
Paricalcitol—Cough—Docetaxel—melanoma	0.00017	0.00132	CcSEcCtD
Paricalcitol—Diarrhoea—Carmustine—melanoma	0.00017	0.00131	CcSEcCtD
Paricalcitol—Pruritus—Temozolomide—melanoma	0.000169	0.00131	CcSEcCtD
Paricalcitol—Nausea—Bleomycin—melanoma	0.000169	0.0013	CcSEcCtD
Paricalcitol—Hypertension—Docetaxel—melanoma	0.000169	0.0013	CcSEcCtD
Paricalcitol—Vomiting—Dactinomycin—melanoma	0.000168	0.0013	CcSEcCtD
Paricalcitol—VDR—Direct p53 effectors—APC—melanoma	0.000167	0.00196	CbGpPWpGaD
Paricalcitol—Rash—Dactinomycin—melanoma	0.000167	0.00129	CcSEcCtD
Paricalcitol—Arthralgia—Docetaxel—melanoma	0.000166	0.00128	CcSEcCtD
Paricalcitol—Chest pain—Docetaxel—melanoma	0.000166	0.00128	CcSEcCtD
Paricalcitol—Myalgia—Docetaxel—melanoma	0.000166	0.00128	CcSEcCtD
Paricalcitol—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	0.000165	0.00128	CcSEcCtD
Paricalcitol—Dizziness—Carmustine—melanoma	0.000164	0.00127	CcSEcCtD
Paricalcitol—Diarrhoea—Temozolomide—melanoma	0.000164	0.00127	CcSEcCtD
Paricalcitol—CYP3A4—Irinotecan Pathway—APC—melanoma	0.000164	0.00191	CbGpPWpGaD
Paricalcitol—Dry mouth—Docetaxel—melanoma	0.000163	0.00126	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism—HS3ST5—melanoma	0.000162	0.00189	CbGpPWpGaD
Paricalcitol—Confusional state—Docetaxel—melanoma	0.000161	0.00124	CcSEcCtD
Paricalcitol—Oedema—Docetaxel—melanoma	0.000159	0.00123	CcSEcCtD
Paricalcitol—Dizziness—Temozolomide—melanoma	0.000158	0.00122	CcSEcCtD
Paricalcitol—Infection—Docetaxel—melanoma	0.000158	0.00122	CcSEcCtD
Paricalcitol—VDR—Generic Transcription Pathway—NPPA—melanoma	0.000158	0.00184	CbGpPWpGaD
Paricalcitol—Vomiting—Carmustine—melanoma	0.000158	0.00122	CcSEcCtD
Paricalcitol—Nausea—Dactinomycin—melanoma	0.000157	0.00122	CcSEcCtD
Paricalcitol—Shock—Docetaxel—melanoma	0.000157	0.00121	CcSEcCtD
Paricalcitol—Rash—Carmustine—melanoma	0.000156	0.00121	CcSEcCtD
Paricalcitol—Nervous system disorder—Docetaxel—melanoma	0.000156	0.00121	CcSEcCtD
Paricalcitol—Dermatitis—Carmustine—melanoma	0.000156	0.00121	CcSEcCtD
Paricalcitol—Headache—Carmustine—melanoma	0.000155	0.0012	CcSEcCtD
Paricalcitol—Skin disorder—Docetaxel—melanoma	0.000155	0.0012	CcSEcCtD
Paricalcitol—VDR—Direct p53 effectors—RB1—melanoma	0.000155	0.00181	CbGpPWpGaD
Paricalcitol—Vomiting—Temozolomide—melanoma	0.000152	0.00118	CcSEcCtD
Paricalcitol—UGT1A4—Metabolism—ACER3—melanoma	0.000152	0.00178	CbGpPWpGaD
Paricalcitol—Anorexia—Docetaxel—melanoma	0.000152	0.00117	CcSEcCtD
Paricalcitol—Rash—Temozolomide—melanoma	0.000151	0.00117	CcSEcCtD
Paricalcitol—Dermatitis—Temozolomide—melanoma	0.000151	0.00117	CcSEcCtD
Paricalcitol—Headache—Temozolomide—melanoma	0.00015	0.00116	CcSEcCtD
Paricalcitol—Hypotension—Docetaxel—melanoma	0.000149	0.00115	CcSEcCtD
Paricalcitol—VDR—Direct p53 effectors—MMP2—melanoma	0.000148	0.00174	CbGpPWpGaD
Paricalcitol—Nausea—Carmustine—melanoma	0.000147	0.00114	CcSEcCtD
Paricalcitol—Musculoskeletal discomfort—Docetaxel—melanoma	0.000145	0.00112	CcSEcCtD
Paricalcitol—Insomnia—Docetaxel—melanoma	0.000144	0.00111	CcSEcCtD
Paricalcitol—Paraesthesia—Docetaxel—melanoma	0.000143	0.00111	CcSEcCtD
Paricalcitol—VDR—Regulation of nuclear SMAD2/3 signaling—MYC—melanoma	0.000143	0.00167	CbGpPWpGaD
Paricalcitol—Nausea—Temozolomide—melanoma	0.000142	0.0011	CcSEcCtD
Paricalcitol—Dyspnoea—Docetaxel—melanoma	0.000142	0.0011	CcSEcCtD
Paricalcitol—Somnolence—Docetaxel—melanoma	0.000142	0.00109	CcSEcCtD
Paricalcitol—Dyspepsia—Docetaxel—melanoma	0.00014	0.00108	CcSEcCtD
Paricalcitol—UGT1A4—Metabolism—UGT2B10—melanoma	0.000139	0.00163	CbGpPWpGaD
Paricalcitol—Decreased appetite—Docetaxel—melanoma	0.000138	0.00107	CcSEcCtD
Paricalcitol—Gastrointestinal disorder—Docetaxel—melanoma	0.000138	0.00106	CcSEcCtD
Paricalcitol—Fatigue—Docetaxel—melanoma	0.000137	0.00106	CcSEcCtD
Paricalcitol—Constipation—Docetaxel—melanoma	0.000136	0.00105	CcSEcCtD
Paricalcitol—Pain—Docetaxel—melanoma	0.000136	0.00105	CcSEcCtD
Paricalcitol—VDR—Direct p53 effectors—BCL2—melanoma	0.000134	0.00157	CbGpPWpGaD
Paricalcitol—CYP3A4—Biological oxidations—UGT2B10—melanoma	0.000132	0.00155	CbGpPWpGaD
Paricalcitol—VDR—Direct p53 effectors—MDM2—melanoma	0.000132	0.00154	CbGpPWpGaD
Paricalcitol—Feeling abnormal—Docetaxel—melanoma	0.000131	0.00101	CcSEcCtD
Paricalcitol—Gastrointestinal pain—Docetaxel—melanoma	0.00013	0.00101	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—CYP17A1—melanoma	0.00013	0.00152	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—HS3ST5—melanoma	0.000129	0.00151	CbGpPWpGaD
Paricalcitol—Body temperature increased—Docetaxel—melanoma	0.000126	0.000973	CcSEcCtD
Paricalcitol—Abdominal pain—Docetaxel—melanoma	0.000126	0.000973	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism—PLCB4—melanoma	0.000123	0.00143	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—FASN—melanoma	0.00012	0.00141	CbGpPWpGaD
Paricalcitol—Hypersensitivity—Docetaxel—melanoma	0.000117	0.000907	CcSEcCtD
Paricalcitol—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—melanoma	0.000117	0.00137	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—SLC6A11—melanoma	0.000115	0.00135	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—PIP4K2A—melanoma	0.000115	0.00135	CbGpPWpGaD
Paricalcitol—Asthenia—Docetaxel—melanoma	0.000114	0.000883	CcSEcCtD
Paricalcitol—Pruritus—Docetaxel—melanoma	0.000113	0.000871	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism—MTAP—melanoma	0.000112	0.00131	CbGpPWpGaD
Paricalcitol—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—melanoma	0.000112	0.00131	CbGpPWpGaD
Paricalcitol—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—melanoma	0.000111	0.0013	CbGpPWpGaD
Paricalcitol—VDR—Direct p53 effectors—CDKN1A—melanoma	0.000111	0.0013	CbGpPWpGaD
Paricalcitol—VDR—Direct p53 effectors—PTEN—melanoma	0.000111	0.0013	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—CYP1B1—melanoma	0.00011	0.00128	CbGpPWpGaD
Paricalcitol—Diarrhoea—Docetaxel—melanoma	0.000109	0.000842	CcSEcCtD
Paricalcitol—CYP3A4—Tryptophan metabolism—CYP1B1—melanoma	0.000106	0.00124	CbGpPWpGaD
Paricalcitol—Dizziness—Docetaxel—melanoma	0.000105	0.000814	CcSEcCtD
Paricalcitol—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP17A1—melanoma	0.000102	0.0012	CbGpPWpGaD
Paricalcitol—Vomiting—Docetaxel—melanoma	0.000101	0.000783	CcSEcCtD
Paricalcitol—CYP3A4—Oxidation by Cytochrome P450—CYP17A1—melanoma	0.000101	0.00118	CbGpPWpGaD
Paricalcitol—Rash—Docetaxel—melanoma	0.0001	0.000776	CcSEcCtD
Paricalcitol—Dermatitis—Docetaxel—melanoma	0.0001	0.000775	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism—PHGDH—melanoma	0.0001	0.00117	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—LUM—melanoma	0.0001	0.00117	CbGpPWpGaD
Paricalcitol—Headache—Docetaxel—melanoma	9.98e-05	0.000771	CcSEcCtD
Paricalcitol—VDR—Regulation of nuclear SMAD2/3 signaling—AKT1—melanoma	9.9e-05	0.00116	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—RPS3—melanoma	9.85e-05	0.00115	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—HPSE—melanoma	9.8e-05	0.00115	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—PLCB4—melanoma	9.8e-05	0.00115	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—SNRPE—melanoma	9.7e-05	0.00113	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—SKI—melanoma	9.7e-05	0.00113	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—CUBN—melanoma	9.62e-05	0.00113	CbGpPWpGaD
Paricalcitol—Nausea—Docetaxel—melanoma	9.46e-05	0.000731	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism—SDHD—melanoma	9.29e-05	0.00109	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—CSPG4—melanoma	9.29e-05	0.00109	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—BSG—melanoma	9.29e-05	0.00109	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—PIP4K2A—melanoma	9.22e-05	0.00108	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—SLC6A11—melanoma	9.22e-05	0.00108	CbGpPWpGaD
Paricalcitol—VDR—Generic Transcription Pathway—CDKN2B—melanoma	9.21e-05	0.00108	CbGpPWpGaD
Paricalcitol—VDR—Direct p53 effectors—EGFR—melanoma	9.01e-05	0.00105	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—GPAM—melanoma	9e-05	0.00105	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—MTAP—melanoma	8.97e-05	0.00105	CbGpPWpGaD
Paricalcitol—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—melanoma	8.6e-05	0.00101	CbGpPWpGaD
Paricalcitol—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—melanoma	8.49e-05	0.000993	CbGpPWpGaD
Paricalcitol—CYP3A4—Metapathway biotransformation—AKR1B10—melanoma	8.39e-05	0.000982	CbGpPWpGaD
Paricalcitol—CYP3A4—Phase 1 - Functionalization of compounds—CYP17A1—melanoma	8.28e-05	0.000969	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—PHGDH—melanoma	7.99e-05	0.000935	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—LUM—melanoma	7.99e-05	0.000935	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—HPSE—melanoma	7.84e-05	0.000917	CbGpPWpGaD
Paricalcitol—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—melanoma	7.76e-05	0.000908	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—CUBN—melanoma	7.69e-05	0.0009	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—PLA2G6—melanoma	7.65e-05	0.000895	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—NPPA—melanoma	7.59e-05	0.000888	CbGpPWpGaD
Paricalcitol—VDR—Direct p53 effectors—TP53—melanoma	7.56e-05	0.000885	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—SDHD—melanoma	7.43e-05	0.000869	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—BSG—melanoma	7.43e-05	0.000869	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—CSPG4—melanoma	7.43e-05	0.000869	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—GPAM—melanoma	7.19e-05	0.000842	CbGpPWpGaD
Paricalcitol—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—melanoma	6.97e-05	0.000816	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—VCAN—melanoma	6.87e-05	0.000804	CbGpPWpGaD
Paricalcitol—VDR—Generic Transcription Pathway—NOTCH1—melanoma	6.63e-05	0.000776	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—PIK3CG—melanoma	6.51e-05	0.000761	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—PPARG—melanoma	6.28e-05	0.000735	CbGpPWpGaD
Paricalcitol—VDR—Generic Transcription Pathway—PPARG—melanoma	6.26e-05	0.000732	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—PLA2G6—melanoma	6.12e-05	0.000716	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—CYP17A1—melanoma	5.8e-05	0.000679	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—PIK3CD—melanoma	5.72e-05	0.000669	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—ALB—melanoma	5.65e-05	0.000661	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—HDAC2—melanoma	5.55e-05	0.000649	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—VCAN—melanoma	5.49e-05	0.000643	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—GNA11—melanoma	5.48e-05	0.000641	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—FASN—melanoma	5.36e-05	0.000627	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—SLC5A5—melanoma	5.27e-05	0.000617	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—CD44—melanoma	5.09e-05	0.000596	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—GNAQ—melanoma	5.09e-05	0.000596	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	4.99e-05	0.000583	CbGpPWpGaD
Paricalcitol—CYP3A4—Tryptophan metabolism—MDM2—melanoma	4.97e-05	0.000582	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—PTGS2—melanoma	4.94e-05	0.000578	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—CYP1B1—melanoma	4.88e-05	0.000571	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—CYP17A1—melanoma	4.64e-05	0.000542	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—CDKN2B—melanoma	4.43e-05	0.000519	CbGpPWpGaD
Paricalcitol—CYP3A4—Biological oxidations—CYP17A1—melanoma	4.4e-05	0.000515	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—GNA11—melanoma	4.38e-05	0.000512	CbGpPWpGaD
Paricalcitol—CYP3A4—Metapathway biotransformation—CYP17A1—melanoma	4.34e-05	0.000508	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—PTEN—melanoma	4.31e-05	0.000504	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—FASN—melanoma	4.28e-05	0.000501	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—SLC5A5—melanoma	4.21e-05	0.000493	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—GNAQ—melanoma	4.07e-05	0.000476	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—CD44—melanoma	4.07e-05	0.000476	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—ABCB1—melanoma	4.02e-05	0.00047	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—PRKCA—melanoma	3.99e-05	0.000466	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—ERCC2—melanoma	3.95e-05	0.000463	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—CYP1B1—melanoma	3.9e-05	0.000457	CbGpPWpGaD
Paricalcitol—CYP3A4—Biological oxidations—CYP1B1—melanoma	3.7e-05	0.000433	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—PRKCA—melanoma	3.7e-05	0.000433	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—ERCC2—melanoma	3.67e-05	0.000429	CbGpPWpGaD
Paricalcitol—CYP3A4—Metapathway biotransformation—CYP1B1—melanoma	3.65e-05	0.000427	CbGpPWpGaD
Paricalcitol—VDR—Generic Transcription Pathway—MYC—melanoma	3.57e-05	0.000418	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—ABCB1—melanoma	3.21e-05	0.000376	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—NOTCH1—melanoma	3.19e-05	0.000374	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	3.04e-05	0.000356	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—PPARG—melanoma	3.01e-05	0.000353	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—PRKCA—melanoma	2.96e-05	0.000346	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—ERCC2—melanoma	2.93e-05	0.000343	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—PIK3CG—melanoma	2.9e-05	0.000339	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—PPARG—melanoma	2.8e-05	0.000327	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—PIK3CD—melanoma	2.55e-05	0.000298	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—ALB—melanoma	2.51e-05	0.000294	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—ACER3—melanoma	2.47e-05	0.000289	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—PIK3CG—melanoma	2.32e-05	0.000271	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—UGT2B10—melanoma	2.26e-05	0.000264	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—PPARG—melanoma	2.24e-05	0.000262	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—PIK3CB—melanoma	2.22e-05	0.00026	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—PTGS2—melanoma	2.2e-05	0.000257	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—HS3ST5—melanoma	2.1e-05	0.000246	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—PIK3CD—melanoma	2.04e-05	0.000238	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—ALB—melanoma	2.01e-05	0.000235	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—PTEN—melanoma	1.92e-05	0.000224	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—PIK3CB—melanoma	1.77e-05	0.000208	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—MAPK3—melanoma	1.77e-05	0.000207	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—PTGS2—melanoma	1.76e-05	0.000206	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—MYC—melanoma	1.72e-05	0.000201	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—PLCB4—melanoma	1.59e-05	0.000186	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—PTEN—melanoma	1.53e-05	0.000179	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—SLC6A11—melanoma	1.5e-05	0.000175	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—PIP4K2A—melanoma	1.5e-05	0.000175	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—MTAP—melanoma	1.46e-05	0.00017	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—PIK3CA—melanoma	1.35e-05	0.000158	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—PHGDH—melanoma	1.3e-05	0.000152	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—LUM—melanoma	1.3e-05	0.000152	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—HPSE—melanoma	1.27e-05	0.000149	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—CUBN—melanoma	1.25e-05	0.000146	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—SDHD—melanoma	1.21e-05	0.000141	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—CSPG4—melanoma	1.21e-05	0.000141	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—BSG—melanoma	1.21e-05	0.000141	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—AKT1—melanoma	1.19e-05	0.000139	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—GPAM—melanoma	1.17e-05	0.000137	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—AKT1—melanoma	1.11e-05	0.000129	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—PIK3CA—melanoma	1.08e-05	0.000127	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—PLA2G6—melanoma	9.93e-06	0.000116	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—VCAN—melanoma	8.92e-06	0.000104	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—AKT1—melanoma	8.84e-06	0.000103	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—CYP17A1—melanoma	7.53e-06	8.81e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—GNA11—melanoma	7.11e-06	8.32e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—FASN—melanoma	6.96e-06	8.14e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—SLC5A5—melanoma	6.84e-06	8e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—GNAQ—melanoma	6.61e-06	7.73e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—CD44—melanoma	6.61e-06	7.73e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—CYP1B1—melanoma	6.33e-06	7.41e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—ABCB1—melanoma	5.22e-06	6.1e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—PRKCA—melanoma	4.8e-06	5.62e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—ERCC2—melanoma	4.76e-06	5.57e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—PIK3CG—melanoma	3.76e-06	4.4e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—PPARG—melanoma	3.63e-06	4.25e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—PIK3CD—melanoma	3.31e-06	3.87e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—ALB—melanoma	3.26e-06	3.82e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—PIK3CB—melanoma	2.88e-06	3.37e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—PTGS2—melanoma	2.85e-06	3.34e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—PTEN—melanoma	2.49e-06	2.91e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—PIK3CA—melanoma	1.76e-06	2.06e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—AKT1—melanoma	1.43e-06	1.68e-05	CbGpPWpGaD
